Latest Alzheimer’s Blockbuster Drug Fails to Complete Phase 3 Trials

As has been reported numerous times here at Health Impact News for the past 6 years or so, the pharmaceutical industry has been desperate to find an Alzheimer's drug to market to an aging baby boomer population with ever increasing numbers of Alzheimer's Disease cases. And yet, billions of dollars have been invested in potential drugs only to see these drugs never make it out of the trial phase and come to market, because they do not significantly help Alzheimer's patients. Biogen and their partner Eisai are the latest pharmaceutical companies to throw in the towel regarding their Alzheimer's drug aducanumab, which has failed to make it out of phase 3 trials. Many drug researchers have now abandoned the theory of amyloid plaque accumulation in the brain as the causative factor of Alzheimer’s. Could aducanumab's failure be the last nail in the coffin for this theory, as natural approaches to Alzheimer's such as coconut oil and the ketogenic diet see more positive results?